APT070 inhibits complement activation during in vitro cardiopulmonary bypass | Zendy

R DESILVA | Zendy; Alain Vuylsteke | Zendy; Sarah Fritchley | Zendy; Andrew K. Trull | Zendy; Joel Dunning | Zendy; J. Wallwork | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

APT070 inhibits complement activation during in vitro cardiopulmonary bypass

Author(s) -

R DESILVA,

Alain Vuylsteke,

Sarah Fritchley,

Andrew K. Trull,

Joel Dunning,

J. Wallwork

Publication year - 2006

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2006.03.012

Subject(s) - cardiopulmonary bypass , complement system , in vitro , complement (music) , whole blood , stimulation , inflammation , immune system , inflammatory response , medicine , human blood , chemistry , immunology , pharmacology , anesthesia , biochemistry , complementation , gene , phenotype , physiology

The proteins of the complement cascade play an important role in inflammation and the immune response. They have been shown to be activated during cardiopulmonary bypass (CPB), and may be responsible for the inflammatory response to CPB. We looked at the effect of APT070, an anti-complement agent, on human blood during in vitro CPB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research